Literature DB >> 193661

Human polymorphonuclear leucocytes as mediators of antibody-dependent cellular cytotoxicity to herpes simplex virus-infected cells.

J M Oleske, R B Ashman, S Kohl, S L Shore, S E Starr, P Wood, A J Nahmias.   

Abstract

Human polymorphonuclear leucocytes (PML) were able to mediate antibody-dependent cellular cytotoxicity (ADCC) against target cells acutely infected with type 1 Herpes simplex virus. The reaction mediated by PML occurred more slowly and required higher concentrations of immune serum than that mediated by human mononuclear cells (MC). At the same ratio of effector cells to target cells, PML-mediated ADCC was less than MC-mediated ADCC. The observed relationship between the number of effector cells added, and the number of target cells lysed, showed that cytolysis mediated by both PML and MC was consistent with 'one hit' probability predictions. This suggested that target cell death resulted from an interaction with a single effector cell. The calculated frequency of effector cells in PML preparation was similar to that in MC, approximately 3-5%. Preliminary examination of the nature of the effector cells suggested that they did not comprise a morphologically distinct subclass of PML. These experiments demonstrate a possible new role for PML in host defence against viral infections.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 193661      PMCID: PMC1540941     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  Eosinophils as mediators of antibody-dependent damage to schistosomula.

Authors:  A E Butterworth; R F Sturrock; V Houba; A A Mahmoud; A Sher; P H Rees
Journal:  Nature       Date:  1975-08-28       Impact factor: 49.962

2.  Antibody-dependent cytolysis of chicken erythrocytes by an in vitro-established line of mouse peritoneal macrophages.

Authors:  W S Walker; A Demus
Journal:  J Immunol       Date:  1975-02       Impact factor: 5.422

3.  Antibody-dependent cytolytically active human leukocytes: an analysis of inactivation following in vitro interaction with antibody-coated target cells.

Authors:  H K Ziegler; C S Henney
Journal:  J Immunol       Date:  1975-12       Impact factor: 5.422

4.  Lysis of herpesvirus-infected cells by immune spleen cells.

Authors:  I A Ramshaw
Journal:  Infect Immun       Date:  1975-04       Impact factor: 3.441

5.  Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus.

Authors:  S L Shore; C M Black; F M Melewicz; P A Wood; A J Nahmias
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

6.  Characteristics of the effector cells mediating cytotoxicity against antibody-coated target cells. III. Ultrastructural studies.

Authors:  P L Penfold; A H Greenberg; I M Roitt
Journal:  Clin Exp Immunol       Date:  1976-01       Impact factor: 4.330

7.  Cell-mediated immunity to Herpes simplex in humans: lymphocyte cytotoxicity measured by 51-Cr release from infected cells.

Authors:  A S Russell; J S Percy; T Kovithavongs
Journal:  Infect Immun       Date:  1975-02       Impact factor: 3.441

8.  Lysis of antibody-treated human erythrocytes by human leukocytes and macrophages in tissue culture.

Authors:  G Holm
Journal:  Int Arch Allergy Appl Immunol       Date:  1972

9.  Reticulum cell sarcoma: an effector cell in antibody-dependent cell-mediated immunity.

Authors:  P Ralph; J Prichard; M Cohn
Journal:  J Immunol       Date:  1975-02       Impact factor: 5.422

10.  Antibody-dependent cell-mediated cytotoxicity in humans. I. Characterization of the effector cell.

Authors:  G Trinchieri; P Bauman; M De Marchi; Z Tökés
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

View more
  26 in total

1.  Herpes simplex virus glycoproteins: participation of individual herpes simplex virus type 1 glycoprotein antigens in immunocytolysis and their correlation with previously identified glycopolypeptides.

Authors:  B Norrild; S L Shore; A J Nahmias
Journal:  J Virol       Date:  1979-12       Impact factor: 5.103

2.  Participation of three major glycoprotein antigens of herpes simplex virus type 1 early in the infectious cycle as determined by antibody-dependent cell-mediated cytotoxicity.

Authors:  B Norrild; S L Shore; T L Cromeans; A J Nahmias
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

3.  Neutrophils are mediators of antiviral immunity.

Authors:  B T Rouse; L A Babiuk; P M Henson
Journal:  Experientia       Date:  1978-03-15

4.  Antibody dependent cellular cytotoxicity against coronavirus 229E-infected cells.

Authors:  M J Holmes; K A Callow; R A Childs; D A Tyrrell
Journal:  Br J Exp Pathol       Date:  1986-08

5.  Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.

Authors:  L A Morrison; L Zhu; L G Thebeau
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 6.  Mechanisms of recovery from Herpesvirus infections -a review.

Authors:  B T Rouse; L A Babiuk
Journal:  Can J Comp Med       Date:  1978-10

7.  (2'-5') Oligo A synthetase in human polymorphonuclear cells increased activity in interferon treatment and in viral infections.

Authors:  A Schattner; G Merlin; V Bregman; T Hahn; S Levin; M Revel; D Wallach
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

8.  Human polymorphonuclear leukocyte-mediated cytotoxicity against varicella-zoster virus-infected fibroblasts.

Authors:  T Ihara; S E Starr; M Ito; S D Douglas; A M Arbeter
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

9.  Murine cellular cytotoxicity to syngeneic and xenogeneic herpes simplex virus-infected cells.

Authors:  S Kohl; D B Drath; L S Loo
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

10.  Antibody-dependent cell-mediated cytotoxicity against varicella-zoster virus-infected targets.

Authors:  H Kamiya; S E Starr; A M Arbeter; S A Plotkin
Journal:  Infect Immun       Date:  1982-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.